{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T16:29:04Z","timestamp":1773937744955,"version":"3.50.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,2,11]],"date-time":"2022-02-11T00:00:00Z","timestamp":1644537600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,2,11]],"date-time":"2022-02-11T00:00:00Z","timestamp":1644537600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Diabetol"],"DOI":"10.1007\/s00592-021-01845-0","type":"journal-article","created":{"date-parts":[[2022,2,11]],"date-time":"2022-02-11T16:02:41Z","timestamp":1644595361000},"page":"721-727","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Pregnancy outcomes in women with type 1 diabetes using insulin degludec"],"prefix":"10.1007","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2971-8043","authenticated-orcid":false,"given":"Lene","family":"Ringholm","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicoline Callesen","family":"Do","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Damm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth Reinhardt","family":"Mathiesen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,2,11]]},"reference":[{"key":"1845_CR1","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s11892-018-1054-9","volume":"18","author":"S Bacon","year":"2018","unstructured":"Bacon S, Feig DS (2018) Glucose targets and insulin choice in pregnancy: what has changed in the last decade? Curr Diab Rep 18:77","journal-title":"Curr Diab Rep"},{"key":"1845_CR2","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1002\/dmrr.2730","volume":"32","author":"J de Jong","year":"2016","unstructured":"de Jong J, Garne E, Wender-Ozegowska E, Morgan M, de Jong-van den Berg LT, Wang H (2016) Insulin analogues in pregnancy and specific congenital anomalies: a literature review. Diabetes Metab Res Rev 32:366\u2013375","journal-title":"Diabetes Metab Res Rev"},{"key":"1845_CR3","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1002\/dmrr.1213","volume":"27","author":"ER Mathiesen","year":"2011","unstructured":"Mathiesen ER, Damm P, Jovanovic L et al (2011) Basal insulin analogues in diabetic pregnancy: a literature review and baseline results of a randomised, controlled trial in type 1 diabetes. Diabetes Metab Res Rev 27:543\u2013551","journal-title":"Diabetes Metab Res Rev"},{"key":"1845_CR4","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.2337\/dc11-2264","volume":"35","author":"ER Mathiesen","year":"2012","unstructured":"Mathiesen ER, Hod M, Ivanisevic M et al (2012) Maternal efficacy and safety outcomes in a randomized, controlled trial comparing insulin detemir with NPH insulin in 310 pregnant women with type 1 diabetes. Diabetes Care 35:2012\u20132017","journal-title":"Diabetes Care"},{"key":"1845_CR5","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.2337\/dc21-0472","volume":"44","author":"ER Mathiesen","year":"2021","unstructured":"Mathiesen ER, Ali N, Alibegovic AC et al (2021) Risk of major congenital malformations or perinatal or neonatal death with insulin detemir versus other basal insulins in pregnant women with preexisting diabetes: the real-world EVOLVE study. Diabetes Care 44:2069","journal-title":"Diabetes Care"},{"key":"1845_CR6","doi-asserted-by":"publisher","first-page":"588","DOI":"10.3109\/14767058.2012.743523","volume":"26","author":"NF Callesen","year":"2013","unstructured":"Callesen NF, Damm J, Mathiesen JM, Ringholm L, Damm P, Mathiesen ER (2013) Treatment with the long-acting insulin analogues detemir or glargine during pregnancy in women with type 1 diabetes: comparison of glycaemic control and pregnancy outcome. J Matern Fetal Neonatal Med 26:588\u2013592","journal-title":"J Matern Fetal Neonatal Med"},{"key":"1845_CR7","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1038\/s41574-019-0197-3","volume":"15","author":"L Ringholm","year":"2019","unstructured":"Ringholm L, Damm P, Mathiesen ER (2019) Improving pregnancy outcomes in women with diabetes mellitus: modern management. Nat Rev Endocrinol 15:406\u2013416","journal-title":"Nat Rev Endocrinol"},{"key":"1845_CR8","first-page":"1127","volume":"21","author":"Y Toledano","year":"2018","unstructured":"Toledano Y, Hadar E, Hod M (2018) Pharmacotherapy for hyperglycemia in pregnancy - the new insulins. Diabetes Res Clin Pract 21:1127","journal-title":"Diabetes Res Clin Pract"},{"key":"1845_CR9","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1007\/s40262-014-0165-y","volume":"53","author":"H Haahr","year":"2014","unstructured":"Haahr H, Heise T (2014) A review of the pharmacological properties of insulin degludec and their clinical relevance. Clin Pharmacokinet 53:787\u2013800","journal-title":"Clin Pharmacokinet"},{"key":"1845_CR10","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1111\/dme.12243","volume":"30","author":"BW Bode","year":"2013","unstructured":"Bode BW, Buse JB, Fisher M et al (2013) Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN((R)) Basal-Bolus Type 1): 2-year results of a randomized clinical trial. Diabet Med 30:1293\u20131297","journal-title":"Diabet Med"},{"key":"1845_CR11","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1111\/dom.12298","volume":"16","author":"MJ Davies","year":"2014","unstructured":"Davies MJ, Gross JL, Ono Y et al (2014) Efficacy and safety of insulin degludec given as part of basal-bolus treatment with mealtime insulin aspart in type 1 diabetes: a 26-week randomized, open-label, treat-to-target non-inferiority trial. Diabetes Obes Metab 16:922\u2013930","journal-title":"Diabetes Obes Metab"},{"key":"1845_CR12","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1001\/jama.2017.7115","volume":"318","author":"W Lane","year":"2017","unstructured":"Lane W, Bailey TS, Gerety G et al (2017) Effect of insulin degludec versus insulin glargine U100 on hypoglycemia in patients with type 1 diabetes: the SWITCH 1 randomized clinical trial. JAMA 318:33\u201344","journal-title":"JAMA"},{"key":"1845_CR13","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s40618-018-0926-9","volume":"42","author":"BM Bonora","year":"2019","unstructured":"Bonora BM, Avogaro A, Fadini GP (2019) Exposure to insulin degludec during pregnancy: report of a small series and review of the literature. J Endocrinol Invest 42:345\u2013349","journal-title":"J Endocrinol Invest"},{"key":"1845_CR14","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s13300-018-0532-z","volume":"10","author":"S Hiranput","year":"2019","unstructured":"Hiranput S, Ahmed SH, Macaulay D, Azmi S (2019) Successful outcomes with insulin degludec in pregnancy: a case series. Diabetes Ther 10:283\u2013289","journal-title":"Diabetes Ther"},{"key":"1845_CR15","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1111\/jdi.12721","volume":"9","author":"A Milluzzo","year":"2017","unstructured":"Milluzzo A, Tumminia A, Scalisi NM, Frittitta L, Vigneri R, Sciacca L (2017) Insulin degludec in the first trimester of pregnancy: report of two cases. J Diabetes Investig 9:629","journal-title":"J Diabetes Investig"},{"key":"1845_CR16","first-page":"e5158","volume":"11","author":"A Roman-Gonzalez","year":"2019","unstructured":"Roman-Gonzalez A, Builes-Barrera CA, Aristizabal BA (2019) Exposure to degludec during pregnancy: a case report. Cureus 11:e5158","journal-title":"Cureus"},{"key":"1845_CR17","doi-asserted-by":"publisher","first-page":"100064","DOI":"10.1016\/j.endmts.2020.100064","volume":"1","author":"E Sprio","year":"2021","unstructured":"Sprio E, Lucotti P, Iadarola C, Bellingeri C, Beneventi F, Lovati E (2021) Use of insulin degludec in pregnancy: two case reports and a literature review. Endocr Metab Sci 1:100064","journal-title":"Endocr Metab Sci"},{"key":"1845_CR18","unstructured":"European Medicines Agency Degludec label. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/tresiba-epar-product-information_en.pdf. Accessed on December 7th 2021"},{"key":"1845_CR19","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.diabres.2019.05.004","volume":"152","author":"MF Keller","year":"2019","unstructured":"Keller MF, Vestgaard M, Damm P, Mathiesen ER, Ringholm L (2019) Treatment with the long-acting insulin analog degludec during pregnancy in women with type 1 diabetes: an observational study of 22 cases. Diabetes Res Clin Pract 152:58\u201364","journal-title":"Diabetes Res Clin Pract"},{"key":"1845_CR20","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.2337\/dc21-1182","volume":"44","author":"NC Do","year":"2021","unstructured":"Do NC, Vestgaard M, Asbjornsdottir B et al (2021) Unchanged prevalence of preeclampsia after implementation of prophylactic aspirin for all pregnant women with preexisting diabetes: a prospective cohort study. Diabetes Care 44:2252","journal-title":"Diabetes Care"},{"key":"1845_CR21","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1007\/s00125-019-05002-9","volume":"62","author":"M Vestgaard","year":"2019","unstructured":"Vestgaard M, Asbjornsdottir B, Ringholm L et al (2019) White coat hypertension in early pregnancy in women with pre-existing diabetes: prevalence and pregnancy outcomes. Diabetologia 62:2188\u20132199","journal-title":"Diabetologia"},{"key":"1845_CR22","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2337\/dc07-1066","volume":"31","author":"LR Nielsen","year":"2008","unstructured":"Nielsen LR, Pedersen-Bjergaard U, Thorsteinsson B, Johansen M, Damm P, Mathiesen ER (2008) Hypoglycemia in pregnant women with type 1 diabetes: predictors and role of metabolic control. Diabetes Care 31:9\u201314","journal-title":"Diabetes Care"},{"key":"1845_CR23","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1002\/dmrr.377","volume":"19","author":"U Pedersen-Bjergaard","year":"2003","unstructured":"Pedersen-Bjergaard U, Pramming S, Thorsteinsson B (2003) Recall of severe hypoglycaemia and self-estimated state of awareness in type 1 diabetes. Diabetes Metab Res Rev 19:232\u2013240","journal-title":"Diabetes Metab Res Rev"},{"key":"1845_CR24","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1067\/mob.2003.441","volume":"189","author":"DM Jensen","year":"2003","unstructured":"Jensen DM, Damm P, Sorensen B et al (2003) Pregnancy outcome and prepregnancy body mass index in 2459 glucose-tolerant Danish women. Am J Obstet Gynecol 189:239\u2013244","journal-title":"Am J Obstet Gynecol"},{"key":"1845_CR25","doi-asserted-by":"publisher","first-page":"137","DOI":"10.2337\/dc18-S013","volume":"41","author":"American Diabetes Association","year":"2018","unstructured":"American Diabetes Association (2018) Standards of Medical Care in Diabetes- 2018. Diabetes Care 41:137\u2013143","journal-title":"Diabetes Care"},{"key":"1845_CR26","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1097\/01.AOG.0000437382.03963.88","volume":"122","author":"Hypertension in Pregnancy","year":"2013","unstructured":"Hypertension in Pregnancy (2013) Report of the American College of Obstetricians and Gynecologists\u2019 task force on hypertension in pregnancy. Obstet Gynecol 122:1122\u20131131","journal-title":"Obstet Gynecol"},{"key":"1845_CR27","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1111\/j.1651-2227.1996.tb14164.x","volume":"85","author":"K Marsal","year":"1996","unstructured":"Marsal K, Persson PH, Larsen T, Lilja H, Selbing A, Sultan B (1996) Intrauterine growth curves based on ultrasonically estimated foetal weights. Acta Paediatr 85:843\u2013848","journal-title":"Acta Paediatr"},{"key":"1845_CR28","unstructured":"European Medicines Agency Lispro label. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/004303\/WC500235294.pdf. Accessed on December 7th 2021"},{"key":"1845_CR29","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s00592-008-0024-0","volume":"45","author":"A Lapolla","year":"2008","unstructured":"Lapolla A, Dalfra MG, Spezia R et al (2008) Outcome of pregnancy in type 1 diabetic patients treated with insulin lispro or regular insulin: an Italian experience. Acta Diabetol 45:61\u201366","journal-title":"Acta Diabetol"},{"key":"1845_CR30","unstructured":"European Medicines Agency Lantus label. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000284\/WC500036082.pdf. Accessed on December 7th 2021"},{"key":"1845_CR31","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.2337\/dc12-2480","volume":"36","author":"ER Seaquist","year":"2013","unstructured":"Seaquist ER, Anderson J, Childs B et al (2013) Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care 36:1384\u20131395","journal-title":"Diabetes Care"},{"key":"1845_CR32","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1111\/j.1464-5491.2011.03333.x","volume":"28","author":"HR Murphy","year":"2011","unstructured":"Murphy HR, Steel SA, Roland JM et al (2011) Obstetric and perinatal outcomes in pregnancies complicated by Type 1 and Type 2 diabetes: influences of glycaemic control, obesity and social disadvantage. Diabet Med 28:1060\u20131067","journal-title":"Diabet Med"}],"container-title":["Acta Diabetologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-021-01845-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00592-021-01845-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-021-01845-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T03:01:31Z","timestamp":1744167691000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00592-021-01845-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,11]]},"references-count":32,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,5]]}},"alternative-id":["1845"],"URL":"https:\/\/doi.org\/10.1007\/s00592-021-01845-0","relation":{},"ISSN":["1432-5233"],"issn-type":[{"value":"1432-5233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,11]]},"assertion":[{"value":"5 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"ERM have received fees for giving talks for Novo Nordisk A\/S. ERM, PD and LR are participating in multicenter and multinational clinical studies on the use of insulin in pregnant women with preexisting diabetes in collaboration with Novo Nordisk; no personal honorarium is involved. NCD is funded by Novo Nordisk Foundation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was in accordance with the Helsinki declaration. In addition, the study was approved by The National Committee on Health Research Ethics (H-15019186 and H-15009413) and The Danish Data Protection Agency (2012-58-0004, RH-2015-289, I-Suite: 04305).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standard statement"}},{"value":"All participants gave written informed consent before the data collection.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent disclosure"}}]}}